BAM
ESPR

Belpointe Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Belpointe Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38,000
Closed -$54.7K – 967
2025
Q1 		$54.7K Sell
38,000
-9,000
-19% -$16.6K ﹤0.01% 902
2024
Q4 		$86K Hold
47,000
– – 0.01% 836
2024
Q3 		$77.5K Hold
47,000
– – ﹤0.01% 850
2024
Q2 		$104K Hold
47,000
– – 0.01% 754
2024
Q1 		$126K Buy
+47,000
New +$114K 0.01% 762

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Belpointe Asset Management's ESPR Position: Q2 2025 in Review

Belpointe Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 38,000 shares — an estimated $54.7K sold.

Belpointe Asset Management first reported a position in ESPR in Q1 2024 and held it in 5 quarters. The position peaked at $126K in Q1 2024. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Belpointe Asset Management reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Belpointe Asset Management sold 38,000 Esperion Therapeutics shares in Q2 2025, an estimated $54.7K.
  • Belpointe Asset Management first reported a position in Esperion Therapeutics in Q1 2024 and held it in 5 quarters.
  • Belpointe Asset Management's Esperion Therapeutics position peaked at $126K in Q1 2024.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Belpointe Asset Management's 13F filing for Q2 2025, filed 22 Jul 2025.